Detailed information for compound 32264

Basic information

Technical information
  • TDR Targets ID: 32264
  • Name: N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2- (dimethylaminomethyl)-4-phenylquinoline-3-car boxamide
  • MW: 531.492 | Formula: C28H23F6N3O
  • H donors: 1 H acceptors: 2 LogP: 6.23 Rotable bonds: 9
    Rule of 5 violations (Lipinski): 2
  • SMILES: CN(Cc1nc2ccccc2c(c1C(=O)NCc1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1ccccc1)C
  • InChi: 1S/C28H23F6N3O/c1-37(2)16-23-25(24(18-8-4-3-5-9-18)21-10-6-7-11-22(21)36-23)26(38)35-15-17-12-19(27(29,30)31)14-20(13-17)28(32,33)34/h3-14H,15-16H2,1-2H3,(H,35,38)
  • InChiKey: WLUJISQNPCWVHU-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(dimethylaminomethyl)-4-phenyl-quinoline-3-carboxamide
  • N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(dimethylaminomethyl)-4-phenyl-3-quinolinecarboxamide
  • N-[3,5-bis(trifluoromethyl)benzyl]-2-(dimethylaminomethyl)-4-phenyl-quinoline-3-carboxamide

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens tachykinin receptor 1 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Schistosoma japonicum ko:K04224 tachykinin receptor 3, putative Get druggable targets OG5_137770 All targets in OG5_137770
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Trypanosoma brucei sphingosine 1-phosphate lyase, putative 0.0109 0 0.5
Echinococcus multilocularis sphingosine kinase 1 0.0148 1 1
Schistosoma mansoni sphingosine kinase A B 0.0148 1 1
Mycobacterium tuberculosis Conserved protein 0.0148 1 0.5
Schistosoma mansoni sphingoid long chain base kinase 0.0148 1 1
Trypanosoma cruzi sphingosine 1-phosphate lyase, putative 0.0109 0 0.5
Entamoeba histolytica hypothetical protein, conserved 0.0148 1 1
Trypanosoma cruzi sphingosine 1-phosphate lyase, putative 0.0109 0 0.5
Mycobacterium ulcerans hypothetical protein 0.0148 1 0.5
Leishmania major sphingosine 1-phosphate lyase 0.0109 0 0.5
Brugia malayi Pyridoxal-dependent decarboxylase conserved domain containing protein 0.0109 0 0.5
Loa Loa (eye worm) hypothetical protein 0.0148 1 1

Activities

Activity type Activity value Assay description Source Reference
Binding (binding) = 40 % Inhibition of labeled SP total binding to human Tachykinin receptor 1 expressed in astrocytoma UC11MG cells ChEMBL. 14998319
Binding (binding) = 40 % Inhibition of labeled SP total binding to human Tachykinin receptor 1 expressed in astrocytoma UC11MG cells ChEMBL. 14998319
IC50 (binding) = 0.22 nM Binding affinity against human Tachykinin receptor 1 expressed in astrocytoma UC11MG cells using [125I]- SP radioligand ChEMBL. 14998319
IC50 (binding) = 0.22 nM Binding affinity against human Tachykinin receptor 1 expressed in astrocytoma UC11MG cells using [125I]- SP radioligand ChEMBL. 14998319
IC50 (binding) = 11 nM Inhibition of labeled SP total binding against human Tachykinin receptor 1 expressed in astrocytoma UC11MG cells by the second binding component ChEMBL. 14998319
IC50 (binding) = 11 nM Inhibition of labeled SP total binding against human Tachykinin receptor 1 expressed in astrocytoma UC11MG cells by the second binding component ChEMBL. 14998319

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.